Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Legend Biotech (LEGN) Stock Price & Analysis
181 Followers
LEGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.30 - $77.32
Previous Close$64.24
Volume207.07K
Average Volume (3M)542.21K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$786.03M
Total Debt (Recent Filing)$284.53M
Price to Earnings (P/E)-22.0
Beta0.65
Next Earnings
Mar 15, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding165,067,240
10 Day Avg. Volume428,352
30 Day Avg. Volume542,210
Standard Deviation0.14
R-Squared0.00009
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)14.87
Price to Sales (P/S)90.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$91.00Price Target Upside43.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Legend Biotech News
Pre-EarningsLEGN Upcoming Earnings Report: What to Expect?
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $37.30 and its highest was $77.32 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Currently, no data Available
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Mar 15, 2024 which is in 176 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Aug 15, 2023. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.361 by -$0.209.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 165,067,250 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.361. Following the earnings report the stock price went down -4.833%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Among the largest hedge funds holding Legend Biotech Corporation’s share is RA Capital Management. It holds Legend Biotech Corporation’s shares valued at 432M.
---
Legend Biotech Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.00 (43.50% Upside)
$91.00 (43.50% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Negative
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
88.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
---
Top 5 ETFs holding LEGN
Fidelity Nasdaq Composite Index ETF
$1.23M
Fidelity New Millennium ETF
$261.90K
T. Rowe Price Growth Stock ETF
$125.34K
T. Rowe Price Growth ETF
$34.50K
Up to five ETFs with an Outperform Smart Score that hold LEGN. The ETFs are listed according to market value of LEGN within the ETF
---